Trial | NCT00666354  Report issue

Title

Dose Response and Safety Study of Topical Methotrexate for the Treatment of Fingernail Psoriasis
Phase IIB Dose Response and Safety Study of Topical Formulations of Methotrexate (MQX-5902, MQX-5904 and MQX-5906) in the Treatment of Fingernail Psoriasis

  • Phase

    Phase 2

  • Study Type

    Interventional

  • Status

    Unknown status

  • Intervention/Treatment

    naltrexone ...

  • Study Participants

    83
The purpose of this clinical study is to compare the efficacy and safety of three concentrations of topical methotrexate for the treatment of fingernail psoriasis.
The purpose of this clinical study is to compare, in a controlled fashion, the response to three concentrations of methotrexate in novel topical formulations in the treatment of subjects with psoriasis of the fingernails. Such a determination will be used as the basis for evidence of efficacy and safety of these formulations as a therapeutic treatment for fingernail psoriasis.
Study Started
Oct 31
2007
Primary Completion
Sep 30
2008
Anticipated
Study Completion
Jan 31
2009
Anticipated
Last Update
Feb 10
2009
Estimate

Drug Methotrexate

0.01 gram of topical amphimatrix containing 0.05% methotrexate per affected nail and adjacent skin folds applied daily for three months.

  • Other names: MQX-5906

Drug Methotrexate

0.01 gram of topical amphimatrix containing 0.25% methotrexate per affected nail and adjacent skin folds applied daily for three months.

  • Other names: MQX-5902

Drug Methotrexate

0.01 gram of topical amphimatrix containing 1.0% methotrexate per affected nail and adjacent skin folds applied daily for three months.

  • Other names: MQX-5904

1 Active Comparator

2 Active Comparator

3 Active Comparator

Criteria 

Inclusion Criteria:

Diagnosed moderate fingernail psoriasis of at least two fingernails.
Stable and unchanged psoriasis therapies for 2 months and must not have received methotrexate for 3 months prior to screening.
Female patients who are not 5 years post menopausal or surgically sterile must use appropriate birth control for specified time periods and have negative pregnancy tests.

Exclusion Criteria:

Target or control fingernails that are thicker than 2mm, abnormal or infected (bacterial or fungal).
Patients with immunosuppression, HIV, or neuropathies of the hand.
Use of any methotrexate preparation, any topical anti-psoriatic medications or ultraviolet treatment within 2 months of study visit 1.
Use of more that one 2-week course of oral corticosteroid therapy or one injection during 3 months prior to the screening visit.
Use of manicures or cosmetic nail products during and within 7 days of the start of treatment.
Use of any drug known to have potential for toxicity to a major organ during and within 90 days prior to the start of treatment.
Patients who are nursing, pregnant or plan to become pregnant or father a child within the study time frame including within three months of the last dose of study medication.
No Results Posted